Argo Biopharma inks $5.2 billion deal with Novartis for novel molecules for cardiovascular diseases
Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure,
The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
Nationwide preventive health initiative aims to make cardiovascular screening at age 30 a standard healthcare milestone
The company has supported the initiative since its inception, contributing to screening efforts in around 120 countries
The collaboration is designed to improve clinical outcomes, reduce procedural risks, and expand access to advanced image-guided treatments across a growing range of conditions
The programme integrates simulation-based training, expert-led sessions, and case-based discussions
This includes 14.3 million views on YouTube and 9.8 million views on Meta platforms to amplify preventive heart health message
The trial will enroll up to 42 patients in Finland across four cohorts
Subscribe To Our Newsletter & Stay Updated